Repaglinide Teva: Uses, Dosage & Side Effects
A short-acting oral antidiabetic agent of the meglitinide class, used to control mealtime blood glucose in adults with type 2 diabetes mellitus
Repaglinide Teva is a generic formulation of repaglinide, a rapid-acting oral antidiabetic medication belonging to the meglitinide class (also known as glinides). It is used to lower blood glucose in adults with type 2 diabetes mellitus whose blood sugar cannot be adequately controlled by diet, exercise, and weight reduction alone. Repaglinide works by stimulating the pancreas to release insulin rapidly in response to meals, making it particularly well-suited to control postprandial (after-meal) glucose spikes. Because of its short half-life and flexible mealtime dosing, repaglinide can be used as monotherapy or in combination with metformin when metformin alone is insufficient. Repaglinide Teva requires a prescription and is marketed in the 0.5 mg, 1 mg, and 2 mg tablet strengths.
Quick Facts: Repaglinide Teva
Key Takeaways
- Repaglinide Teva is a short-acting meglitinide used to treat adults with type 2 diabetes mellitus whose blood glucose cannot be controlled by diet, weight loss, and exercise alone; it is often combined with metformin when metformin monotherapy is insufficient.
- It works by rapidly stimulating insulin release from pancreatic beta cells, with onset within 30 minutes and duration of approximately 4 hours, making it ideal for targeting mealtime glucose peaks.
- Doses are taken before each main meal (typically 15 minutes before, with a range of 0 to 30 minutes) and must be skipped whenever a meal is skipped to prevent hypoglycemia.
- The most important side effect is hypoglycemia; risk is increased by missed meals, physical exertion, alcohol intake, liver impairment, and interacting drugs (particularly gemfibrozil and clopidogrel).
- Repaglinide is primarily eliminated by the liver and is therefore a useful option for patients with moderate chronic kidney disease, though caution is needed in hepatic impairment.
What Is Repaglinide Teva and What Is It Used For?
Repaglinide Teva contains repaglinide, a short-acting oral medication used to lower blood glucose in adults with type 2 diabetes mellitus (T2DM). Repaglinide belongs to the meglitinide class of non-sulfonylurea insulin secretagogues, sometimes referred to as “glinides.” It was the first meglitinide approved for clinical use and is included in the British National Formulary, the European Medicines Agency (EMA) centrally authorised product list, and the United States FDA-approved drug directory. The Teva version is a therapeutically equivalent generic formulation, bioequivalent to the originator brand (NovoNorm in Europe, Prandin in the United States).
Type 2 diabetes is a chronic metabolic disorder characterised by insulin resistance in peripheral tissues (muscle, liver, and fat) combined with relative insulin deficiency from progressive failure of the pancreatic beta cells. Affecting approximately 540 million adults worldwide according to the International Diabetes Federation, it is the most common form of diabetes and is strongly associated with excess body weight, sedentary lifestyle, and advancing age. Untreated or poorly controlled type 2 diabetes can lead to microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease (coronary artery disease, stroke, peripheral artery disease).
Repaglinide’s mechanism of action is distinctive among oral antidiabetic agents. It binds to a specific receptor on the beta cell membrane — adjacent to, but distinct from, the sulfonylurea receptor — and closes ATP-sensitive potassium (K-ATP) channels. This depolarises the cell membrane, opens voltage-gated calcium channels, and triggers the release of preformed insulin granules into the bloodstream. Crucially, the binding is rapid, reversible, and glucose-dependent: insulin release is more pronounced in the presence of elevated glucose, which reduces (but does not eliminate) the risk of fasting hypoglycemia compared with longer-acting sulfonylureas.
The pharmacokinetic profile of repaglinide explains its unique clinical role. After oral administration, peak plasma concentrations are reached in approximately 1 hour. The drug is almost completely metabolised by cytochrome P450 enzymes in the liver (primarily CYP3A4 and CYP2C8) to inactive metabolites, which are excreted mainly in the bile. The plasma half-life is approximately 1 hour, and the total duration of glucose-lowering action is around 4 hours. This short time course means each dose covers a single meal, and the drug is effectively cleared before the next meal — a property that allows flexible dosing around meal patterns.
Repaglinide Teva is indicated for adults with type 2 diabetes in whom blood glucose remains elevated despite diet, exercise, and weight reduction. It may be used as monotherapy (single agent) in patients who cannot tolerate metformin, or as combination therapy with metformin when metformin alone is insufficient. It is not indicated for type 1 diabetes, diabetic ketoacidosis, severe hepatic dysfunction, or children. Meglitinides have a relatively modest effect on HbA1c (reduction of approximately 0.5–1.5 percentage points) but excel at targeting postprandial glucose excursions, a clinically important contributor to cardiovascular risk in diabetes.
Compared with sulfonylureas (glibenclamide, gliclazide, glimepiride), repaglinide offers several practical advantages: shorter duration of action (reducing the risk of prolonged overnight hypoglycemia), flexible “one-dose-per-meal” administration (meals can be skipped or delayed without disrupting dosing), and a lower observed rate of severe hypoglycemia in some head-to-head comparisons. On the other hand, it requires more frequent dosing, must be taken consistently with meals, and may be less effective than sulfonylureas in patients who eat predictable meals at fixed times. The choice between agents should be individualised in consultation with a treating physician.
What Should You Know Before Taking Repaglinide Teva?
Contraindications
There are several absolute clinical situations in which Repaglinide Teva must not be used. Recognising these contraindications is essential to prevent severe hypoglycemia, drug toxicity, and treatment failure. Do not take Repaglinide Teva if any of the following apply:
- Hypersensitivity: Known allergy to repaglinide or any of the excipients in the tablet formulation.
- Type 1 diabetes mellitus: Repaglinide requires functioning pancreatic beta cells to produce insulin and is therefore ineffective in type 1 diabetes, where the beta cells have been largely destroyed by autoimmune processes.
- Diabetic ketoacidosis (DKA): A medical emergency characterised by severe hyperglycemia, ketone accumulation, and metabolic acidosis. DKA requires urgent insulin therapy, not meglitinides.
- Severe hepatic impairment: The liver is the principal site of repaglinide metabolism. Severe liver dysfunction markedly prolongs drug exposure and increases the risk of hypoglycemia.
- Concurrent use of gemfibrozil: This lipid-lowering drug is a potent inhibitor of CYP2C8, one of the main enzymes that metabolises repaglinide. Combined use can increase repaglinide exposure up to eight-fold, producing severe and prolonged hypoglycemia. The combination is considered contraindicated in EMA, FDA, and BNF labeling.
- Pregnancy: Repaglinide is not recommended during pregnancy because of limited safety data; insulin is the treatment of choice.
- Breastfeeding: It is unknown whether repaglinide passes into human breast milk; treatment should be avoided in nursing mothers.
- Age under 18 years: Safety and effectiveness have not been established in children and adolescents.
Warnings and Precautions
Repaglinide can cause hypoglycemia (low blood sugar), which may be severe and occasionally requires emergency treatment. The risk is highest when meals are delayed or skipped, during unusual physical activity, with alcohol consumption, in the elderly, in patients with hepatic impairment, and when combined with other glucose-lowering medications. Symptoms include sweating, trembling, rapid heartbeat, intense hunger, blurred vision, confusion, difficulty concentrating, and slurred speech. Untreated severe hypoglycemia can progress to seizures and loss of consciousness. Always carry a fast-acting source of sugar such as glucose tablets or fruit juice.
Because repaglinide stimulates insulin release, hypoglycemia is the expected and most clinically important adverse effect. Unlike metformin and several newer agents (such as DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists), repaglinide carries a real and recurrent risk of hypoglycemia, particularly when its use is not synchronised with meals. The short duration of action partially mitigates this risk, but episodes can still occur at any dose and may be severe. Clinical studies have shown that symptomatic hypoglycemia occurs in around 25–30% of treated patients at some point during therapy, though severe events requiring third-party assistance are considerably rarer (approximately 1–2% annually).
Hepatic impairment is a major consideration. Because repaglinide is almost entirely metabolised by the liver, patients with liver disease may experience accumulation of the drug with an increased risk of severe hypoglycemia. Caution is advised in patients with mild to moderate liver impairment, and repaglinide should not be used in severe hepatic dysfunction (Child-Pugh class C). Liver enzyme monitoring is advisable in patients with known liver disease.
Renal impairment affects repaglinide differently from many other diabetes medications. Because the drug is primarily cleared by the liver and excreted in the bile rather than the urine, repaglinide does not accumulate to a clinically significant degree in chronic kidney disease. This makes it a reasonable option for patients with reduced kidney function, in whom metformin and several sulfonylureas are contraindicated. However, insulin sensitivity tends to increase as renal function declines, which can lower the required dose. Start with 0.5 mg and titrate cautiously, particularly in dialysis patients.
Acute illness (severe infection, surgery, trauma, or major emotional stress) can cause marked fluctuations in blood glucose and may reduce the effectiveness of oral antidiabetic drugs. During such episodes, repaglinide may need to be replaced temporarily with insulin to achieve adequate glycemic control. If you undergo planned surgery, your doctor will advise whether to continue, pause, or switch your diabetes medication before and after the procedure.
As with other oral antidiabetic agents, the glucose-lowering effect of repaglinide may diminish over time. “Primary failure” refers to inadequate initial response despite dose titration; “secondary failure” refers to loss of effectiveness after initial success, usually reflecting the progressive beta-cell dysfunction characteristic of type 2 diabetes. If repaglinide is no longer providing adequate glycemic control, your doctor may add, switch to, or combine it with other therapies — including metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin.
Elderly patients are at particular risk of hypoglycemia because of impaired counter-regulatory responses, polypharmacy, irregular meal patterns, and reduced renal or hepatic reserve. Although no formal age-based dose adjustment is required, treatment should generally begin at the lowest dose (0.5 mg) and be titrated slowly with close monitoring of blood glucose and clinical symptoms.
Regular self-monitoring of blood glucose (SMBG) is strongly recommended while taking repaglinide, especially at initiation, during dose adjustments, and at times of altered eating patterns, physical activity, or acute illness. Understanding how to recognise and treat hypoglycemia is an essential part of safe therapy. Continuous glucose monitoring (CGM) systems can be particularly valuable for detecting asymptomatic hypoglycemia and guiding dose adjustments.
Pregnancy and Breastfeeding
Repaglinide is not recommended during pregnancy. There are no adequate and well-controlled clinical trials in pregnant women, and animal studies have shown some developmental effects at high doses. If you are pregnant, think you may be pregnant, or are planning to become pregnant, you should speak with your doctor about alternative diabetes treatment. Insulin remains the mainstay for managing hyperglycemia in pregnancy because it does not cross the placenta and has a long history of safe use. Pre-pregnancy planning, including glycemic optimization and folic acid supplementation, is strongly recommended for all women with diabetes of reproductive age.
It is not known whether repaglinide is excreted in human breast milk, but it has been shown to pass into the milk of lactating rats. Because of the potential risk to the nursing infant, repaglinide should not be used during breastfeeding. If treatment is necessary, breastfeeding should be discontinued, or an alternative agent with an established breastfeeding safety profile should be chosen after consulting your healthcare provider.
Driving and Operating Machinery
Repaglinide can cause hypoglycemia, which may impair your ability to drive safely or operate dangerous machinery. Symptoms such as dizziness, visual disturbances, reduced concentration, and slowed reaction time can appear suddenly. You should take precautions to avoid low blood sugar while driving, particularly if you have frequent hypoglycemia, reduced awareness of the warning signs (hypoglycemia unawareness), or are driving for long periods. Check your blood glucose before driving and again during long journeys, and always carry fast-acting sugar in the vehicle. If you experience symptoms of hypoglycemia while driving, pull over safely as soon as possible, stop the engine, treat the hypoglycemia, and wait at least 45 minutes after normal glucose is restored before continuing.
How Does Repaglinide Teva Interact with Other Drugs?
Repaglinide is metabolised primarily by two hepatic cytochrome P450 enzymes, CYP3A4 and CYP2C8, and is a substrate of the hepatic uptake transporter OATP1B1. Drugs that inhibit or induce these enzymes and transporters can therefore substantially alter repaglinide blood levels and its glucose-lowering effect. Other interactions involve additive pharmacological effects, such as amplified hypoglycemia when repaglinide is combined with other glucose-lowering agents, or blunted hypoglycemia symptoms when combined with beta-blockers.
Major Interactions (Contraindicated or Serious)
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Gemfibrozil (lipid-lowering) | Potent CYP2C8 inhibition; up to 8-fold increase in repaglinide plasma levels with severe, prolonged hypoglycemia | Contraindicated. Do not combine under any circumstances |
| Clopidogrel (antiplatelet) | Clopidogrel metabolite strongly inhibits CYP2C8, increasing repaglinide exposure 3–5 fold and hypoglycemia risk | Avoid if possible; otherwise use the minimum repaglinide dose with close glucose monitoring |
| Ciclosporin (immunosuppressant) | Inhibits OATP1B1 uptake and CYP3A4; roughly doubles repaglinide exposure | Use lower repaglinide dose; monitor blood glucose carefully |
| Itraconazole, ketoconazole, clarithromycin (strong CYP3A4 inhibitors) | Reduce repaglinide metabolism, raising plasma levels and hypoglycemia risk | Avoid combination if possible; if unavoidable, start with the lowest repaglinide dose and monitor glucose closely |
| Trimethoprim (antibiotic; component of co-trimoxazole) | CYP2C8 inhibition increases repaglinide exposure; increased hypoglycemia risk | Avoid combination; use alternative antibiotic when possible |
| Deferasirox (iron chelator) | Moderate CYP2C8 and CYP3A4 inhibition; significantly raises repaglinide exposure | Avoid combination; if required, reduce repaglinide dose and monitor glucose closely |
Moderate and Other Notable Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Rifampicin (antibiotic) | Potent CYP3A4 inducer; reduces repaglinide exposure by up to 50%, decreasing effectiveness | Dose increase may be required; monitor blood glucose and re-titrate dose when rifampicin is stopped |
| Phenytoin, carbamazepine, rifampin, barbiturates (enzyme inducers) | Accelerate repaglinide metabolism, reducing glucose-lowering effect | Closer glucose monitoring; dose adjustment may be required |
| Beta-blockers (propranolol, atenolol, metoprolol) | Can mask adrenergic warning symptoms of hypoglycemia (tachycardia, tremor, palpitations) | Patient education on non-adrenergic symptoms (sweating, hunger, confusion); more vigilant glucose monitoring |
| ACE inhibitors (enalapril, ramipril, lisinopril) | May enhance insulin sensitivity and the glucose-lowering effect of antidiabetics | Monitor blood glucose when starting, stopping, or changing the ACE inhibitor dose |
| Salicylates, NSAIDs, MAO inhibitors, octreotide | May enhance the glucose-lowering effect of repaglinide | Monitor blood glucose more frequently; dose adjustment may be needed |
| Corticosteroids, thiazide diuretics, oral contraceptives, thyroid hormones, sympathomimetics | Can raise blood glucose, weakening repaglinide’s effect | Monitor blood glucose; repaglinide dose may need adjustment during and after co-administration |
| Other antidiabetic drugs (insulin, sulfonylureas) | Additive glucose-lowering effect; significantly increased hypoglycemia risk | Combination should be carefully managed by a physician; dose of the other agent may need reduction |
| Alcohol | Can prolong and intensify hypoglycemic episodes, especially with fasting | Limit alcohol intake, especially on an empty stomach; never binge drink |
This list is not exhaustive. Always tell your doctor and pharmacist about every medicine, herbal product, and dietary supplement you take. Some over-the-counter medicines and herbal remedies (including St John’s wort, which induces CYP3A4, and various weight-loss products that affect glucose metabolism) can interact meaningfully with repaglinide. Before starting any new medication, ask whether it is safe to combine with your current diabetes treatment.
What Is the Correct Dosage of Repaglinide Teva?
The dose of Repaglinide Teva is highly individualised. It should always be prescribed and adjusted by a healthcare professional based on your fasting and postprandial blood glucose, glycated haemoglobin (HbA1c), body weight, eating patterns, renal and hepatic function, and concomitant medications. Because repaglinide acts quickly and for only a few hours, its dosing is tied directly to meals: one dose, one meal — no meal, no dose.
Adults
Adult Dosage (18 years and over)
- Starting dose: 0.5 mg before each main meal in patients not previously treated with oral antidiabetics
- Switching from another oral antidiabetic: 1 mg before each main meal is commonly used
- Dose adjustment: Titrate upwards every 1–2 weeks based on blood glucose response, typically doubling the previous dose
- Maximum single dose: 4 mg per meal
- Maximum daily dose: 16 mg
- Typical number of daily doses: 2–4 (one before each main meal)
The medicine is normally taken 15 minutes before each main meal, but this window can range from immediately before eating to 30 minutes before, depending on patient preference. The flexibility is a key clinical advantage: patients who eat an extra meal can take an extra dose, and those who skip a meal simply skip that dose. The Repaglinide Teva 0.5 mg tablet is commonly used for initial titration or for patients particularly sensitive to hypoglycemia.
When repaglinide is added to metformin therapy, the metformin dose is usually continued unchanged and repaglinide is added starting at 0.5 mg before meals, with gradual upward titration. If repaglinide is being substituted for another oral agent, the previous drug should be discontinued on the day repaglinide is started; no overlap is necessary because of repaglinide’s rapid onset of action.
Children and Adolescents
Pediatric Use
- Not recommended. Safety and effectiveness of repaglinide have not been established in children and adolescents under 18 years of age.
- In young people with type 2 diabetes, metformin is the preferred first-line oral agent, with insulin used as needed.
Pediatric type 2 diabetes is best managed through a multidisciplinary approach that includes structured lifestyle intervention, metformin (the only widely approved oral agent in this age group), and insulin if required. Repaglinide is not approved for use in children because of insufficient data on safety, dose-response, and long-term developmental outcomes.
Elderly Patients, Renal and Hepatic Impairment
Special Populations
- Elderly (65+): No specific dose adjustment required, but start at 0.5 mg and titrate cautiously. Greater susceptibility to hypoglycemia.
- Renal impairment: No dose adjustment for mild-to-moderate impairment. Increased insulin sensitivity in severe renal impairment may call for a lower starting dose (0.5 mg) and careful titration.
- Mild-to-moderate hepatic impairment: Use with caution; longer intervals between dose adjustments are recommended to allow full assessment of response.
- Severe hepatic impairment: Contraindicated.
- Debilitated or malnourished patients: Initial and maintenance doses should be conservative; these patients are particularly susceptible to hypoglycemia.
Elderly patients often take multiple medications, eat irregularly, and have reduced physiological reserve, which places them at higher risk of hypoglycemia. Clinical monitoring should include regular review of blood glucose trends, symptoms of hypoglycemia (including atypical presentations such as falls or confusion), renal and liver function tests, and a careful review of other prescribed medications at least once a year.
How to Take Repaglinide Teva
Swallow each tablet whole with a glass of water, preferably 15 minutes before a main meal. The drug should not be crushed or chewed. A typical regimen involves one tablet before breakfast, one before lunch, and one before the evening meal, although the exact timing and number of doses will be tailored to your eating habits and glucose profile. If you eat four main meals per day, a fourth dose may be added; if you eat only two main meals, only two doses are taken.
- Two main meals: Take one dose before each main meal.
- Three main meals: Take one dose before each of breakfast, lunch, and dinner.
- Four main meals: Take one dose before each meal, but do not exceed 16 mg total per day.
- Skipped meal: Skip the corresponding dose — do not take it later or with the next meal.
- Additional meal: Take an additional dose before the extra meal, within the maximum daily dose.
Repaglinide Teva cannot replace the benefits of a healthy lifestyle. Continue to follow any dietary and exercise advice from your healthcare team, avoid smoking, maintain a healthy body weight, and attend regular follow-up appointments. A balanced diet with appropriate carbohydrate distribution across meals is particularly important for matching the drug’s action to glucose intake.
Missed Dose
If you forget a dose before a meal, take it as soon as you remember, but only if you have just started or are still eating the meal. Do not take the missed dose between meals, and do not double a later dose to compensate. If you have already finished eating and an hour or more has passed, skip the dose entirely and resume your normal schedule at the next meal. Taking repaglinide outside mealtimes substantially increases the risk of hypoglycemia without providing additional benefit.
Overdose
Overdose with repaglinide causes severe and potentially prolonged hypoglycemia, which is a medical emergency. Symptoms include profuse sweating, intense hunger, trembling, rapid heartbeat, confusion, drowsiness, difficulty speaking, blurred vision, seizures, and loss of consciousness. If you or someone you care for has taken too much repaglinide, seek emergency medical attention immediately. In mild cases, oral glucose (sweet juice, glucose tablets, sugary drinks) may be sufficient if the person is conscious. In severe or unconscious patients, intravenous dextrose and/or intramuscular glucagon are required.
Because the glucose-lowering effect of repaglinide is dose-related, overdose produces a predictable and serious hypoglycemic response. Importantly, hypoglycemia can recur after initial treatment, particularly if a large dose was taken, so a period of inpatient observation (typically 24–48 hours) with serial blood glucose monitoring and intravenous dextrose infusion may be required. There is no specific antidote, and repaglinide is not effectively removed by dialysis due to its high protein binding. Supportive care and continuous glucose supplementation are the cornerstones of management.
What Are the Side Effects of Repaglinide Teva?
Like all medicines, Repaglinide Teva can cause side effects, although not everyone experiences them. Side effects are described below according to their frequency, following the Council for International Organizations of Medical Sciences (CIOMS) classification used by the EMA. Most adverse reactions are mild to moderate in severity and resolve either with dose adjustment or with the passage of time. Hypoglycemia is the most important clinical concern and is directly related to the pharmacological action of the drug.
Very Common
May affect more than 1 in 10 people
- Hypoglycemia (low blood sugar) — especially if a meal is skipped, delayed, or smaller than usual, or with unaccustomed physical activity
Common
May affect up to 1 in 10 people
- Abdominal pain, diarrhea
- Nausea, constipation, vomiting (less frequent)
Uncommon
May affect up to 1 in 100 people
- Severe hypoglycemia requiring third-party assistance or emergency care
- Dizziness, headache
- Transient increase in liver enzymes (aminotransferases)
Rare
May affect up to 1 in 1,000 people
- Cardiovascular events (causality not firmly established; type 2 diabetes itself is a major cardiovascular risk factor)
- Visual disturbances, particularly at the start of treatment due to changing glucose levels affecting the lens
Very Rare
May affect up to 1 in 10,000 people
- Hypersensitivity reactions: generalised skin rash, itching (pruritus), redness (erythema), hives (urticaria), vasculitis
- Severe liver dysfunction, hepatitis, cholestatic jaundice
- Pancreatitis
Recognising and Managing Hypoglycemia
Hypoglycemia is the most important side effect of repaglinide. Early (autonomic) symptoms include sweating, trembling, rapid heartbeat, hunger, anxiety, and tingling of the lips. Later (neuroglycopenic) symptoms, reflecting glucose deprivation of the brain, include confusion, difficulty concentrating, behavioural changes, slurred speech, blurred vision, drowsiness, and ultimately seizures and loss of consciousness. The threshold for symptoms varies between individuals; people with frequent hypoglycemia may develop hypoglycemia unawareness, in which autonomic warning symptoms are blunted or absent.
For conscious patients, mild-to-moderate hypoglycemia is treated with 15–20 g of fast-acting carbohydrate (for example, three to four glucose tablets, 150–200 mL of fruit juice, or 150–200 mL of a regular soft drink), followed by a snack or meal containing longer-acting carbohydrate once blood glucose has recovered above 4 mmol/L (70 mg/dL). Recheck blood glucose after 15 minutes and repeat the treatment if still low. For severe hypoglycemia with impaired consciousness, intramuscular or subcutaneous glucagon (for those with training or a family member trained to administer it) or intravenous dextrose should be used, and emergency medical assistance should be sought immediately.
Visual Disturbances at Treatment Initiation
Some patients experience transient visual changes — typically blurred vision or difficulty focusing — during the first few weeks of treatment. This is generally due to fluctuations in lens hydration as blood glucose levels stabilise, rather than a direct drug effect. Vision usually returns to baseline once glucose is stable. Do not change your glasses prescription during this settling-in period; wait until glycemic control has been stable for several weeks. Contact an eye health professional promptly if visual symptoms are severe, persistent, or include sudden loss of vision.
Long-Term Safety
Over decades of clinical use since its original approval in the late 1990s, repaglinide has been found to have an acceptable long-term safety profile. Unlike some sulfonylureas, it has not been conclusively associated with increased cardiovascular mortality, though rigorous cardiovascular outcome trials directly comparing repaglinide with newer agents are limited. Weight gain of approximately 1–3 kg over the first year of therapy is common, reflecting reduced urinary glucose loss and improved metabolic efficiency. Bone mineral density, cancer risk, and cognitive outcomes appear neutral in published observational studies. Reporting of any new or unexpected symptoms to your healthcare provider contributes to ongoing pharmacovigilance.
How Should You Store Repaglinide Teva?
Repaglinide Teva tablets should be stored at a temperature below 25 °C (77 °F) in their original packaging. The blister pack and outer carton protect the tablets from moisture and light, which can affect the stability of the active ingredient. Do not transfer the tablets to another container, and do not remove them from the blister until immediately before use. Avoid storing the medication in humid environments (such as bathroom cabinets) or in direct sunlight.
Keep Repaglinide Teva out of the sight and reach of children. Accidental ingestion by a child can cause severe hypoglycemia and requires urgent medical evaluation. If a child accidentally takes repaglinide, contact emergency services or a poison control centre immediately and provide the exact dose and time of ingestion.
Do not use Repaglinide Teva after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of the stated month. Expired medications may have reduced effectiveness and potentially altered safety. Do not dispose of medications in household waste or wastewater. Return unused or expired tablets to your pharmacy or a medication take-back programme; your pharmacist will dispose of them safely and in accordance with local environmental regulations. These measures help to protect the environment and prevent accidental exposure.
What Does Repaglinide Teva Contain?
The active substance in Repaglinide Teva tablets is repaglinide. Each tablet contains either 0.5 mg, 1 mg, or 2 mg of repaglinide as the free base. The molecule is a carbamoylmethyl benzoic acid derivative and is chemically distinct from sulfonylureas, although both drug classes act on pancreatic K-ATP channels.
| Tablet Strength | Repaglinide Content | Typical Appearance |
|---|---|---|
| 0.5 mg | 0.5 mg | White to off-white, round, uncoated |
| 1 mg | 1 mg | Beige to yellow, round, uncoated (iron oxide yellow) |
| 2 mg | 2 mg | Pink, round, uncoated (iron oxide red) |
Typical inactive ingredients (excipients) in Repaglinide Teva tablets include:
- Fillers: Microcrystalline cellulose, maize starch, mannitol, calcium hydrogen phosphate
- Binders: Povidone (polyvinylpyrrolidone)
- Disintegrants: Croscarmellose sodium, sodium starch glycolate
- Lubricants: Magnesium stearate, glyceryl behenate
- Colorants (1 mg and 2 mg tablets): Iron oxide yellow (E172) or iron oxide red (E172)
- Other: Meglumine, poloxamer (in some formulations)
If you have a known sensitivity to any of these excipients, review the full ingredients list on the patient information leaflet supplied with your specific pack. The exact composition may vary between different manufacturers and over time. Patients intolerant to specific inactive ingredients should consult their pharmacist or prescriber to identify a suitable alternative formulation.
Frequently Asked Questions About Repaglinide Teva
Repaglinide Teva is a short-acting oral antidiabetic medication used to treat type 2 diabetes mellitus in adults when diet, exercise, and weight loss alone cannot adequately control blood glucose. It belongs to the meglitinide (glinide) class and works by stimulating rapid insulin release from the pancreas at mealtimes. It is typically taken 15 minutes before meals and can be used as monotherapy or in combination with metformin when metformin alone is insufficient.
Although both repaglinide and sulfonylureas stimulate insulin secretion from the pancreas, repaglinide has a much faster onset (within 30 minutes) and shorter duration of action (approximately 4 hours). This allows flexible mealtime dosing — a dose is taken only when a meal is eaten and skipped when a meal is skipped. Sulfonylureas, by contrast, act for 12–24 hours and are typically taken at fixed times regardless of meal timing. Repaglinide is therefore often preferred for patients with irregular eating patterns and may carry a slightly lower risk of prolonged fasting hypoglycemia.
The most common side effect is hypoglycemia (low blood sugar), with symptoms including sweating, trembling, hunger, palpitations, and dizziness. Other common side effects include abdominal pain, diarrhea, and mild upper respiratory tract symptoms. Mild transient increases in liver enzymes, visual disturbances at the start of treatment, and skin reactions have also been reported. Serious but rare reactions include severe hypoglycemia, hypersensitivity reactions, and hepatic dysfunction.
If you skip a meal, you must also skip the corresponding dose of Repaglinide Teva. Taking the medication without food can cause severe hypoglycemia. This flexible dosing schedule — one dose per meal, no meal means no dose — is one of the main advantages of meglitinides over longer-acting sulfonylureas. Never take an extra dose to make up for a missed one. Always carry a fast-acting source of sugar (glucose tablets or juice) in case of hypoglycemia.
Yes. Unlike many sulfonylureas, repaglinide is primarily eliminated through the bile and feces with minimal renal excretion, which makes it a relatively safer option for patients with moderate chronic kidney disease. However, insulin sensitivity may be increased in severe renal impairment, so initial doses should be low (0.5 mg) and titrated cautiously. Regular blood glucose monitoring is essential, and treatment should always be supervised by a physician familiar with your kidney status.
Alcohol can both prolong and intensify the hypoglycemic effect of repaglinide, particularly when consumed on an empty stomach or during binge drinking. Moderate alcohol intake with food may be acceptable for some patients, but it is always safer to discuss limits with your doctor. Avoid alcohol altogether if you have liver disease, frequent hypoglycemia, or are taking other medications that can interact with either repaglinide or alcohol. If you choose to drink, check your blood glucose before, during, and several hours after, and make sure someone nearby knows how to help you in case of hypoglycemia.
Mild weight gain (typically 1–3 kg) can occur in the first year of treatment, which is consistent with other insulin secretagogues. The mechanism includes reduced glucose loss in the urine and improved metabolic efficiency as glucose control improves. Combining repaglinide with metformin may attenuate the weight gain, and continuing structured diet and physical activity is important. If weight gain is problematic, discuss alternative regimens — such as adding an SGLT2 inhibitor or a GLP-1 receptor agonist — with your healthcare provider.
References
This article is based on current international medical guidelines and peer-reviewed scientific literature. All medical claims are supported by evidence level 1A, the highest quality of evidence based on systematic reviews and randomised controlled trials.
- American Diabetes Association (ADA). Standards of Medical Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1). Comprehensive annual guidelines for the management of diabetes mellitus.
- European Medicines Agency (EMA). NovoNorm (repaglinide) — Summary of Product Characteristics. Updated 2025. Official European regulatory document for repaglinide.
- U.S. Food and Drug Administration (FDA). Prandin (repaglinide tablets) — Prescribing Information. Updated 2024. Official U.S. regulatory document for repaglinide.
- Joint Formulary Committee. British National Formulary (BNF) — Repaglinide. London: BMJ Group and Pharmaceutical Press; updated quarterly.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024. UK clinical guidelines addressing the role of meglitinides.
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034
- Black C, Donnelly P, McIntyre L, Royle P, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD004654. doi:10.1002/14651858.CD004654.pub2
- Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by gemfibrozil: roles of glucuronidation and thiol conjugation. Drug Metab Dispos. 2011;39(10):1977–1983. doi:10.1124/dmd.111.039032
- Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of repaglinide. Drug Metab Dispos. 2008;36(1):73–80. doi:10.1124/dmd.107.018010
- International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th Edition. Brussels: IDF; 2021. Global epidemiology of diabetes mellitus.
- Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 2001;24(6):983–988. doi:10.2337/diacare.24.6.983
- Tornio A, Filppula AM, Niemi M, Backman JT. Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. Clin Pharmacol Ther. 2019;105(6):1345–1361. doi:10.1002/cpt.1435
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specialist qualifications in endocrinology, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and adheres to international medical standards set by the WHO, EMA, FDA, and ADA.
All articles undergo a rigorous multi-step review process: initial drafting by medical writers, clinical accuracy review by specialist physicians, evidence grading according to the GRADE framework, and final editorial quality assurance. Content is updated regularly to reflect new guidelines, research findings, and safety information.
iMedic follows Evidence Level 1A standards, drawing from systematic reviews, meta-analyses, and randomised controlled trials published in peer-reviewed journals. We reference established clinical guidelines from international medical organizations including the ADA, EASD, WHO, EMA, FDA, and NICE.
For questions about our editorial process or to report inaccuracies, please visit our Editorial Standards page or contact our editorial team.